A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DD-S052P in Healthy Volunteers
Latest Information Update: 04 Feb 2026
At a glance
- Drugs DD S052P (Primary)
- Indications Gram-negative infections; Sepsis
- Focus Adverse reactions; First in man
- Sponsors HLB LifeScience
Most Recent Events
- 04 Feb 2026 New trial record